X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with J.B.Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs J.B.CHEMICALS - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

J.B.CHEMICALS 
   Change

JB Chemicals and Pharmaceuticals Limited (JBCPL), the flagship of the Unique Group, is one of the India's leading transnational pharmaceutical company. The company has 11 manufacturing facilities at four locations in India (Belapur, Ankleshwar, Panol... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA J.B.CHEMICALS SUN PHARMA/
J.B.CHEMICALS
 
P/E (TTM) x 24.5 19.2 127.6% View Chart
P/BV x 2.6 2.0 130.9% View Chart
Dividend Yield % 0.5 0.6 82.1%  

Financials

 SUN PHARMA   J.B.CHEMICALS
EQUITY SHARE DATA
    SUN PHARMA
Mar-18
J.B.CHEMICALS
Mar-18
SUN PHARMA/
J.B.CHEMICALS
5-Yr Chart
Click to enlarge
High Rs701363 192.9%   
Low Rs433255 169.9%   
Sales per share (Unadj.) Rs110.4169.1 65.3%  
Earnings per share (Unadj.) Rs11.016.6 66.1%  
Cash flow per share (Unadj.) Rs17.223.4 73.6%  
Dividends per share (Unadj.) Rs2.002.00 100.0%  
Dividend yield (eoy) %0.40.6 54.5%  
Book value per share (Unadj.) Rs158.8172.5 92.1%  
Shares outstanding (eoy) m2,399.2683.57 2,871.0%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x5.11.8 281.0%   
Avg P/E ratio x51.618.6 277.3%  
P/CF ratio (eoy) x32.913.2 249.3%  
Price / Book Value ratio x3.61.8 199.2%  
Dividend payout %18.212.0 151.2%   
Avg Mkt Cap Rs m1,360,02125,827 5,265.8%   
No. of employees `00017.83.8 471.6%   
Total wages/salary Rs m53,6712,511 2,137.4%   
Avg. sales/employee Rs Th14,890.93,747.4 397.4%   
Avg. wages/employee Rs Th3,017.1665.7 453.2%   
Avg. net profit/employee Rs Th1,480.6367.8 402.6%   
INCOME DATA
Net Sales Rs m264,89514,135 1,874.0%  
Other income Rs m8,388366 2,292.9%   
Total revenues Rs m273,28214,501 1,884.6%   
Gross profit Rs m56,0812,178 2,574.5%  
Depreciation Rs m14,998570 2,632.7%   
Interest Rs m5,17635 14,830.1%   
Profit before tax Rs m44,2951,940 2,283.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-9,5050-   
Tax Rs m8,452552 1,530.3%   
Profit after tax Rs m26,3381,387 1,898.6%  
Gross profit margin %21.215.4 137.4%  
Effective tax rate %19.128.5 67.0%   
Net profit margin %9.99.8 101.3%  
BALANCE SHEET DATA
Current assets Rs m316,35910,470 3,021.6%   
Current liabilities Rs m198,6432,749 7,226.0%   
Net working cap to sales %44.454.6 81.4%  
Current ratio x1.63.8 41.8%  
Inventory Days Days9555 171.8%  
Debtors Days Days10878 138.7%  
Net fixed assets Rs m213,1785,811 3,668.4%   
Share capital Rs m2,399167 1,435.8%   
"Free" reserves Rs m378,60614,248 2,657.2%   
Net worth Rs m381,00614,416 2,643.0%   
Long term debt Rs m17,7210-   
Total assets Rs m643,02817,649 3,643.4%  
Interest coverage x9.656.6 16.9%   
Debt to equity ratio x00-  
Sales to assets ratio x0.40.8 51.4%   
Return on assets %4.98.1 60.8%  
Return on equity %6.99.6 71.8%  
Return on capital %10.013.7 73.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m40,8166,164 662.2%   
Fx outflow Rs m30,1431,334 2,258.9%   
Net fx Rs m10,6734,829 221.0%   
CASH FLOW
From Operations Rs m39,0721,231 3,175.3%  
From Investments Rs m-33,708-208 16,198.0%  
From Financial Activity Rs m-15,393-595 2,586.1%  
Net Cashflow Rs m-7,359427 -1,723.0%  

Share Holding

Indian Promoters % 63.7 55.4 115.0%  
Foreign collaborators % 0.0 0.3 -  
Indian inst/Mut Fund % 5.1 3.4 151.3%  
FIIs % 23.0 3.9 589.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 37.0 22.4%  
Shareholders   133,026 30,437 437.1%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   WOCKHARDT  FULFORD INDIA  DR. REDDYS LAB  BIOCON   UNICHEM LAB  

Compare SUN PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

US China Trade War Escalations and Election Results: Volatility Set to Rule(Podcast)

India could be the latest direct victim of the US-China trade war. The increasing escalations have already slowed down global growth.

Related Views on News

J.B.CHEMICALS 2017-18 Annual Report Analysis (Annual Result Update)

Mar 28, 2019 | Updated on Mar 28, 2019

Here's an analysis of the annual report of J.B.CHEMICALS for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of J.B.CHEMICALS. Also includes updates on the valuation of J.B.CHEMICALS.

SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 20, 2018 | Updated on Dec 20, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 110.7% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, SUN PHARMA has posted a net profit of Rs 1 bn (down 110.7% YoY). Sales on the other hand came in at Rs 69 bn (up 4.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 446.1% (Quarterly Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

For the quarter ended June 2018, SUN PHARMA has posted a net profit of Rs 11 bn (up 446.1% YoY). Sales on the other hand came in at Rs 72 bn (up 16.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

These Dividend Stocks Could Boost Your Returns Better Than You Can Imagine(Profit Hunter)

May 7, 2019

The art of dividend investing is a lot more than investing in companies with high dividend payouts or stocks with high dividend yields...

Limited Upside, Higher Downside(The Honest Truth)

May 6, 2019

The market's irrational reaction may present opportunities for a limited period of time.

3 Indian Stocks Replicating Amazon's Successful Strategy(The 5 Minute Wrapup)

May 10, 2019

The one critical element that has made Amazon a force to reckon with...

A Simple Checklist for Picking Great Dividend Stocks(Profit Hunter)

May 9, 2019

A filtered, neat list of high-dividend stocks with all this dirty work already done for you.

My Top 7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)

May 16, 2019

Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


May 17, 2019 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE SUN PHARMA WITH

MARKET STATS